Abaxis (Abaxis) Change In Working Capital : $-6.7 Mil (TTM As of Mar. 2018)

View and export this data going back to 1992. Start your Free Trial

What is Abaxis Change In Working Capital?

Abaxis's change in working capital for the quarter that ended in Mar. 2018 was $-8.0 Mil.

Abaxis's change in working capital for the fiscal year that ended in Mar. 2018 was $-6.7 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Abaxis Change In Working Capital Historical Data

The historical data trend for Abaxis's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis Change In Working Capital Chart

Abaxis Annual Data

Trend

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Change In Working Capital

Get a 7-Day Free Trial

9.23

0.99

-21.63

-11.87

-6.71

Abaxis Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Change In Working Capital	Get a 7-Day Free Trial															-1.02	0.94	0.54	-0.19	-8.00

Abaxis Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.7 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Abaxis Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Abaxis's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Abaxis (Abaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.abaxis.com

Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.

Executives

Richard Bastiani	director	C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr	officer: CFO and VP of Finance	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson	director, officer: CEO & Board Chairman	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey	director	ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020